Aardvark Therapeutics, Inc. (AARD)
NASDAQ: AARD · Real-Time Price · USD
13.56
+1.16 (9.35%)
At close: Dec 5, 2025, 4:00 PM EST
13.16
-0.40 (-2.95%)
After-hours: Dec 5, 2025, 6:34 PM EST
Aardvark Therapeutics Stock Forecast
Stock Price Forecast
The 8 analysts with 12-month price forecasts for Aardvark Therapeutics stock have an average target of 30.63, with a low estimate of 18 and a high estimate of 50. The average target predicts an increase of 125.88% from the current stock price of 13.56.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Aardvark Therapeutics stock from 8 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 3 | 4 | 5 | 5 |
| Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 6 | 7 | 8 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| RBC Capital | RBC Capital | Buy Maintains $19 → $18 | Buy | Maintains | $19 → $18 | +32.74% | Nov 14, 2025 |
| BTIG | BTIG | Strong Buy Initiates $26 | Strong Buy | Initiates | $26 | +91.74% | Nov 7, 2025 |
| Jones Trading | Jones Trading | Strong Buy Initiates $33 | Strong Buy | Initiates | $33 | +143.36% | Oct 1, 2025 |
| Stifel | Stifel | Strong Buy Initiates $24 | Strong Buy | Initiates | $24 | +76.99% | Sep 29, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $40 | Strong Buy | Reiterates | $40 | +194.99% | Sep 23, 2025 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
510.00K
EPS This Year
-3.01
from -5.15
EPS Next Year
-3.73
from -3.01
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | n/a | 3.2M | ||||
| Avg | n/a | 510,000 | ||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -2.82 | -2.09 | ||||
| Avg | -3.01 | -3.73 | ||||
| Low | -3.06 | -5.70 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.